Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

venetoclax 136Cytarabine 106Cyclophosphamide 104Specimen Handling 94fludarabine 86Azacitidine 84Biopsy 71Rituximab 45Methotrexate 42Daunorubicin 41fludarabine phosphate 40Vincristine 35Magnetic Resonance Spectroscopy 35Dexamethasone 35blinatumomab 31Injections 31Decitabine 31Granulocyte Colony-Stimulating Factor 29Mycophenolic Acid 28Whole-Body Irradiation 27Idarubicin 27ibrutinib 26Tacrolimus 26Prednisone 26Etoposide 26Busulfan 25Melphalan 24Doxorubicin 24acalabrutinib 23Calcium Dobesilate 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Daptomycin × Other hematologic neoplasm × 90 days × Clear all
NCT04983901 2026-04-06

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 38 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡